IBDEI1Y5 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,33043,1,3,0)
 ;;=3^Immunization Admin,1 Vaccine
 ;;^UTILITY(U,$J,358.3,33044,0)
 ;;=90472^^130^1663^2^^^^1
 ;;^UTILITY(U,$J,358.3,33044,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,33044,1,2,0)
 ;;=2^90472
 ;;^UTILITY(U,$J,358.3,33044,1,3,0)
 ;;=3^Immunization Admin,Ea Addl
 ;;^UTILITY(U,$J,358.3,33045,0)
 ;;=B18.2^^131^1664^26
 ;;^UTILITY(U,$J,358.3,33045,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33045,1,3,0)
 ;;=3^Hepatitis C,Chr
 ;;^UTILITY(U,$J,358.3,33045,1,4,0)
 ;;=4^B18.2
 ;;^UTILITY(U,$J,358.3,33045,2)
 ;;=^5000548
 ;;^UTILITY(U,$J,358.3,33046,0)
 ;;=C44.99^^131^1664^50
 ;;^UTILITY(U,$J,358.3,33046,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33046,1,3,0)
 ;;=3^Skin Cancer,Unspec
 ;;^UTILITY(U,$J,358.3,33046,1,4,0)
 ;;=4^C44.99
 ;;^UTILITY(U,$J,358.3,33046,2)
 ;;=^5001094
 ;;^UTILITY(U,$J,358.3,33047,0)
 ;;=E11.9^^131^1664^15
 ;;^UTILITY(U,$J,358.3,33047,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33047,1,3,0)
 ;;=3^Diabetes Type 2
 ;;^UTILITY(U,$J,358.3,33047,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,33047,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,33048,0)
 ;;=E11.40^^131^1664^16
 ;;^UTILITY(U,$J,358.3,33048,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33048,1,3,0)
 ;;=3^Diabetes Type 2 w/ Neuropathy
 ;;^UTILITY(U,$J,358.3,33048,1,4,0)
 ;;=4^E11.40
 ;;^UTILITY(U,$J,358.3,33048,2)
 ;;=^5002644
 ;;^UTILITY(U,$J,358.3,33049,0)
 ;;=E78.2^^131^1664^27
 ;;^UTILITY(U,$J,358.3,33049,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33049,1,3,0)
 ;;=3^Hyperlipidemia,Mixed
 ;;^UTILITY(U,$J,358.3,33049,1,4,0)
 ;;=4^E78.2
 ;;^UTILITY(U,$J,358.3,33049,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,33050,0)
 ;;=E78.5^^131^1664^28
 ;;^UTILITY(U,$J,358.3,33050,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33050,1,3,0)
 ;;=3^Hyperlipidemia,Unspec
 ;;^UTILITY(U,$J,358.3,33050,1,4,0)
 ;;=4^E78.5
 ;;^UTILITY(U,$J,358.3,33050,2)
 ;;=^5002969
 ;;^UTILITY(U,$J,358.3,33051,0)
 ;;=E66.3^^131^1664^44
 ;;^UTILITY(U,$J,358.3,33051,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33051,1,3,0)
 ;;=3^Overweight
 ;;^UTILITY(U,$J,358.3,33051,1,4,0)
 ;;=4^E66.3
 ;;^UTILITY(U,$J,358.3,33051,2)
 ;;=^5002830
 ;;^UTILITY(U,$J,358.3,33052,0)
 ;;=D64.9^^131^1664^3
 ;;^UTILITY(U,$J,358.3,33052,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33052,1,3,0)
 ;;=3^Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,33052,1,4,0)
 ;;=4^D64.9
 ;;^UTILITY(U,$J,358.3,33052,2)
 ;;=^5002351
 ;;^UTILITY(U,$J,358.3,33053,0)
 ;;=F17.200^^131^1664^41
 ;;^UTILITY(U,$J,358.3,33053,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33053,1,3,0)
 ;;=3^Nicotine Dependence,Unspec
 ;;^UTILITY(U,$J,358.3,33053,1,4,0)
 ;;=4^F17.200
 ;;^UTILITY(U,$J,358.3,33053,2)
 ;;=^5003360
 ;;^UTILITY(U,$J,358.3,33054,0)
 ;;=F17.229^^131^1664^38
 ;;^UTILITY(U,$J,358.3,33054,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33054,1,3,0)
 ;;=3^Nicotine Dependence,Chewing Tobacco
 ;;^UTILITY(U,$J,358.3,33054,1,4,0)
 ;;=4^F17.229
 ;;^UTILITY(U,$J,358.3,33054,2)
 ;;=^5003374
 ;;^UTILITY(U,$J,358.3,33055,0)
 ;;=F19.10^^131^1664^53
 ;;^UTILITY(U,$J,358.3,33055,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33055,1,3,0)
 ;;=3^Substance Abuse,Unspec
 ;;^UTILITY(U,$J,358.3,33055,1,4,0)
 ;;=4^F19.10
 ;;^UTILITY(U,$J,358.3,33055,2)
 ;;=^5003416
 ;;^UTILITY(U,$J,358.3,33056,0)
 ;;=F15.10^^131^1664^52
 ;;^UTILITY(U,$J,358.3,33056,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33056,1,3,0)
 ;;=3^Stimulant Abuse,Unspec
 ;;^UTILITY(U,$J,358.3,33056,1,4,0)
 ;;=4^F15.10
 ;;^UTILITY(U,$J,358.3,33056,2)
 ;;=^5003282
 ;;^UTILITY(U,$J,358.3,33057,0)
 ;;=F43.21^^131^1664^2
 ;;^UTILITY(U,$J,358.3,33057,1,0)
 ;;=^358.31IA^4^2
